Oncotelic Doses First Patient in Phase 1b Trial of Sapu003 for Solid Tumors
May 13, 2026 — Oncotelic Therapeutics (OTLC) and Sapu Nano dose first patient in Phase 1b trial of Sapu003, a IV everolimus formulation for advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer.